Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma
Male
0303 health sciences
Science
Gene Expression Profiling
Q
R
610
Infant
Prognosis
Risk Assessment
Progression-Free Survival
004
3. Good health
Gene Expression Regulation, Neoplastic
Neuroblastoma
03 medical and health sciences
Deep Learning
Medicine
Humans
Female
Neoplasm Recurrence, Local
Child
Algorithms
Research Article
DOI:
10.1371/journal.pone.0208924
Publication Date:
2018-12-07T18:25:30Z
AUTHORS (4)
ABSTRACT
We introduce the CDRP (Concatenated Diagnostic-Relapse Prognostic) architecture for multi-task deep learning that incorporates a clinical algorithm, e.g., risk stratification schema to improve prognostic profiling. present first application survival prediction in High-Risk (HR) Neuroblastoma from transcriptomics data, task studies MAQC consortium have shown remain hardest among multiple diagnostic and endpoints predictable same dataset. To obtain more accurate needed appropriate treatment strategies, combines component (CDRP-A) synthesizing second (CDRP-N) dedicated one or tasks. The approach leverages advent of semi-supervised structures can flexibly integrate multimodal data internally create processing paths. CDRP-A is an autoencoder trained on gene expression HR/non-HR by Children's Oncology Group, obtaining 64-node representation bottleneck layer. CDRP-N classifier two endpoints, i.e., Event-Free Survival (EFS) Overall (OS). provides HR embedding input shared layer, which branches depart model EFS OS, respectively. control selection bias, evaluated using Data Analysis Protocol (DAP) developed within initiative. was applied Illumina RNA-Seq 498 patients (HR: 176) SEQC study (12,464 Entrez genes) Affymetrix Human Exon Array profiles (17,450 247 primary TARGET NBL cohort. On patients, achieves Matthews Correlation Coefficient (MCC) 0.38 MCC = 0.19 OS external validation, improving over published models. show indeed parametrically associated increasing severity be used better stratify patients' survival.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (18)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....